In randomized clinical trials of breast and colorectal cancer, new effective adjuvant treatments show decreasing absolute benefit, while new treatments of metastatic disease show unchanging levels of benefit at rapidly escalating costs.
The current research and treatment model makes no difference in outcomes, but adds a lot of profit to researchers, oncologists and pharmaceuticals. How about targeting "individuals" with "individualized" therapy?
From Annals of Oncology
http://www.medscape.com/viewarticle/...?src=emailthis
Threaded Mode